Bactiguard Holding (BACTI-B) Fair Value & Analysis
Healthcare · SE · Market cap 568M SEK (≈ $59.4M) · ISIN SE0005878741
What is Bactiguard Holding really worth?
Below-average quality, and trading another 21% above our fair value of kr 13.17.
Risks
Fair value as of: Aug 17, 2026
From 3 valuation models · updated 19 days ago
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (kr 8.92 to kr 17.42) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.
How to read this chart
60‑month range kr 14.10 – kr 197.40 · fair‑value band kr 8.92 – kr 17.42 · the kr 16.00 price screens above the kr 13.17 fair value. Dashed = 300-day average. As of Aug 17, 2026.
Analysis
Bactiguard Holding (BACTI-B) currently trades at kr 16.00, while our model-based Fair Value estimate is kr 13.17, implying the stock looks roughly 21.5% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of kr 26.09 per share, and 1 of the 3 models we run sit above the kr 16.00 price. Bear case: the Asset-Based group reads lowest at kr 6.80, and 2 of the 3 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Bactiguard Holding generated revenue of 201M SEK at a net margin of −4.3%. Revenue declined 28.1% year over year. It earns a return on equity of −2.8%. Net debt stands at 119M SEK. Fundamentals as of Aug 17, 2026
Our scenario range runs from kr 8.92 (bear case) to kr 17.42 (bull case); at kr 16.00, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −18%, BACTI-B screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 3 models by family
Widest divergence: DCF Models (kr 26.09) versus Asset-Based (kr 6.80). Highest evidence: Owner Earnings (71).
Notify me when BACTI-B reaches fair value
Put BACTI-B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas.
Full company description
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for acute, chronic, and infected wounds; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company has licensed partnership with Becton, Dickinson & Company for urinary catheter bardex IC and lubrisil IC; Well Lead Medical for catheters and tubes; and Zimmer Biomet for orthopedic trauma implants. It operates in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. The company was founded in 2005 and is headquartered in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bactiguard Holding reported revenue of 216M SEK in FY2025 versus 169M SEK in FY2021, a compound +6.2%/yr. Reported net income was −7.8M SEK in FY2025.
BACTI-B screens 21% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare Bactiguard Holding with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Bactiguard Holding (BACTI-B) overvalued or undervalued?
What is the fair value of BACTI-B?
What is the quality score of BACTI-B?
What is the revenue of Bactiguard Holding (BACTI-B)?
What is the net profit margin of BACTI-B?
Watch Bactiguard Holding in the live analysis
One click puts Bactiguard Holding on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.